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Value of booster immunisation with
influenza vaccine in patients undergoing
haemodialysis
The public health authorities ofmost Western countries recommend annual
influenza vaccination for some patients, including those with end stage renal
disease.' Patients on haemodialysis, however, show impaired antibody
responses after a single influenza vaccination, which may result in in-
sufficient protection.2 These patients also respond poorly to hepatitis B
vaccine, but a booster immunisation will produce protective antibody titres.3
In a large group of patients on haemodialysis we therefore attempted to
induce adequate protection against influenza by performing a booster
vaccination.
Patients, methods, and results
Ninety eight patients in a stable condition who were undergoing long term
intermittent haemodialysis took-part. They were aged 17 to 76 (median 57) years
and had been undergoing haemodialysis for one month to 13 years (median two
years). None had received steroids or immunosuppressive drugs for at least six
months. Twenty nine healthy volunteers aged 19 to 69 (median 27) years served as
controls. A commercially available trivalent split virus vaccine (Alorbat,
Asta Werken, Bielefeld, Federal Republic of Germany) containing 15 Isg
haemagglutinin of A/Philippines/2/82 (H3N2), A/Chile/l/83 (HIN,), and
B/USSR/100/83 was administered by intramuscular injection in the upper arm on
day 0 and day 30 (booster immunisation). Serum was obtained on days 0, 30, and
60. The study took place in the autumn of 1985. Antibody titres were determined
twice in paired sera by the haemagglutination inhibition technique, and
geometric mean titres were calculated. A fourfold or more rise in titre was
considered to be a satisfactory response, and protection was defined by titres of
>-100 against influenza A and ¢200 against ether treated influenza B.4
Before vaccination geometric mean titres against the three virus strains did not
differ between the groups (table). After the first injection the patients undergoing
dialysis had significantly lower geometric mean titres than the controls for all
viruses tested (p<0-001, Wilcoxon rank test). Booster vaccination did not
influence the final titres reached.
Among the initially unprotected patients and controls significantly fewer of the
patients showed a more than fourfold rise in titre against the three viruses (H3N2
and B p<0*05, HIN1 p<0001; x2 test) after the first injection (table). Booster
immunisation produced greater than fourfold rises in titres against H3N2, HIN,
and B in, respectively, a further 14%, 8%, and 0% ofthe patients and 5%, 8%, and
4% of the controls. The seroconversion rate to protective titres against H3N2 and
B was also significantly lower among the patients after the first injection than
among the controls (p<0-001, x2 test). Booster immunisation increased the
seroconversion rate among the patients but not significantly so. Together the first
and second vaccinations induced adequate protective antibody titres in 81 (83%)
of the patients for H3N2, 37 (38%) for HINI, and 47 (48%) for B. The statistical
significance of the results measured as geometric mean titres, more than fourfold
rises in titres, and seroconversion rates was maintained when controls were
compared with age and sex matched patients undergoing dialysis.
Comment
In patients undergoing haemodialysis vaccination with an influenza
vaccine was significantly less effective than in the controls for all three
Effects offirst injection and booster vaccination with influenza vaccine on mean log
geometric mean titre against influenza viruses H3N2, H,NI, and B in patients
undergoing haemodialysis and controls, and greater than fourfold rises in titres and
seroconverson rates to protective titres in individuals with unprotective prevaccination
titres
Patients (n=98) Controls (n=29)
H3N2 HIN, B H3N2 HIN, B
Mean log geometric mean titre:
Beforefirstinjection 1-10 1-67 1-28 1-14 1-12 1-14
After first injection 2-21 1-66 2-05 2-93 2-39 2-63
After booster vaccination 2-30 1-68 2-05 3-01 2-47 2-62
No (%) with non-protective titres
before vaccination 71 (72) 88(90) 82 (84)20f(69) 25 (86) 25 (86)
No (%) with sfourfold rise in titre:
After first injection 49(69) 39(44) 47(57) 19(95) 21 (84) 20(80)
After second injection 59(83) 46(52) 47(57) 20(100) 23(92) 21 (84)
Seroconversion rate (No (%)):
Afer first injection 47(66) 22 (25) 22(27) 17(85) 21 (84) 19(76)
Afer booster vaccination 54(76) 27(31) 31 (38) 18 (90) 22(88) 20(80)
viruses. The better conversion rate to protective titres against H3N2 in the
patients can be explained by a "priming" effect, as the H3N2 strains have
circulated for over 10 years and have caused several epidemics in the
Netherlands. Booster immunisation only marginally improved the efficacy
ofvaccination against the three influenza viruses in both the patients and the
controls. Only a small minority of the 98 patients developed protective titres
as a result of the second immunisation: seven for H3N2, five for HINI, and
nine for B. Therefore we cannot recommend a booster immunisation with
influenza vaccine in patients undergoing dialysis. Prophylactic amantadine
therapy, which protects against influenza A viruses but not against influenza
B, may be considered for these patients if an epidemic is imniinent.I
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Neuropathy of the feet due to running on
cold surfaces
After running a race in bare feet on a day when the temperature was below
freezing several runners presented to hospital with injuries to their feet.
Such injuries have not been reported before.
Patients and findings
In February 1986, 160 runners took part in a sponsored five mile run; all had to
run in bare feet. The participants were members of a karate club, and most of
them had run in bare feet on previous occasions without any problems. The
course was along paths in a park in Leicester; at the start of the race the ambient
temperature was -50C and the ground temperature -9°C (United Kingdom
Meteorological Office, personal communication). All the runners finished the
event without any problems. Shortly afterwards, however, 25 participants
presented to the accident and emergency department with almost identical
injuries to their feet.
All the patients complained of severe pain in their feet, which had developed
shortly after they finished the race. On examination the weightbearing surfaces of
the soles of their feet were bright red and deeply ingrained with dirt. The areas
affected resembled partial thickness bums. Large tense blisters were also found
in several patients; debridement of these showed partial thickness skin loss
(figure).
Comment
Most of the patients had taken part in similar runs before but never on a
freezing day. In the past they had experienced pain in their feet during the
run and on finding blistering had stopped. On this particular day pain had
been absent during the event and the skin damage had not become apparent
until some time afterwards.
